Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hyaluronan mediated motility receptor (RHAMM; also known as HMMR or IHABP) is a cell surface and intracellular protein that binds to hyaluronan—a major component of the extracellular matrix. It plays a critical role in regulating cell motility, migration, and proliferation. When hyaluronan binds to RHAMM, it triggers phosphorylation events involving proteins such as PTK2/FAK1 and can activate the ERK signaling pathway. This receptor is implicated in processes like inflammation, wound healing, tissue remodeling, and especially cancer progression by promoting cellular transformation and metastasis formation. Multiple isoforms exist due to alternative splicing; some are associated with aggressive tumor phenotypes when localized in the nucleus or on the cell surface. The primary endogenous ligand for this target is hyaluronic acid itself[4][1].
Binding of hyaluronan to RHAMM activates intracellular signaling pathways such as phosphorylation of PTK2/FAK1 and ERK pathway, influencing cell migration and proliferation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hyaluronan mediated motility receptor (RHAMM).